Resistant Hypertension by Prkačin, Ingrid et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
Resistant Hypertension
Ingrid Prkačin, Diana Rudan, Tomo Svaguša,
Matija Bakoš and Zrinko Šalek
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.73004
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Ingrid Prkačin, Diana Rudan, Tomo Svaguša, 
Matija Bakoš and Zrinko Šalek
Additional information is available at the end of the chapter
Abstract
The most common causes of therapeutic failure in hypertensive control are undiscovered 
secondary causes of hypertension and lack of patient/doctor compliance. In about 10% 
of cases, it can be attributed to resistant hypertension caused by a hyperactivity of the 
sympathetic nervous system, condition with a high cardiovascular risk to the patient. 
Resistant hypertension is failure to diminish blood pressure values to <140/90 mmHg 
(<140/85 mmHg for diabetic patients) with a lifestyle method and prescription of least 
three antihypertensive drugs in optimal doses, including a diuretic, or when patients use 
four or more antihypertensive drugs regardless of blood pressure control. Patients with 
resistant hypertension are typically presented with a long-standing history of poorly con-
trolled hypertension. Early diagnosis and adequate treatment are needed to avoid end 
organ damage and to prevent cardiorenovascular remodeling. Cardiorenovascular mor-
bidity and mortality are significantly higher in resistant hypertensive population. The 
need for the individualization of therapy and the use of the management strategies are 
also given weight in the treatment of resistant hypertension patients, including optional, 
innovative therapies, like a renal denervation or baroreflex activation. New innovative 
device therapies create an additional novel pathway of blood pressure-lowering proce-
dures and should be prescribed by a specialist hypertension clinic.
Keywords: resistant hypertension, adherence, cardiorenovascular risk, sympathetic 
activation, innovative device therapies
1. Introduction
Hypertension is chronic disease and is extremely complex. Hypertension has the largest 
prevalence of 30–45% of all cardiovascular risk factors. The achievement of blood pressure 
values below 140/90 mmHg is considered one of the main methods of achieving high long-
term patient quality of life. Hypertension has an extreme phenotype, especially resistant 
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hypertension. Genetic factors may play a great role. Some genes have been associated with 
failure to antihypertensive medication treatment. Environmental factors contribute to the 
development of resistant hypertension—making importance of epigenetic. Resistant hyper-
tension is a consequence of different pathophysiologic processes that are associated with 
high cardiovascular risk as consequences of increased stimulation of renin-angiotensin sys-
tem and aldosterone production [1]. Arterial stiffness and atherosclerotic disease are also 
common in resistant hypertension patients. If pharmacological therapy with at least three 
antihypertensive drugs in optimal doses, including a diuretic, fails to reduce the office blood 
pressure to below 140/90 mmHg, patient suffer from drug-resistant hypertension [1, 2]. There 
are two types of drug-resistant hypertension: controlled and uncontrolled. Uncontrolled 
resistant hypertension patients cannot achieve blood pressure under 140/90 mmHg despite 
the use of three and more antihypertensive drugs (one of them being diuretic) and optimal 
lifestyle changes. The prevalence has been estimated between 8 and 13% of all antihyperten-
sive drug-treated patients [2]. In last 50 years, the use of antihypertensive drugs has revo-
lutionized the therapy of hypertension. Despite the available pharmacological inhibition of 
the sympathetic nervous system, about 50% of patients show suboptimal control, and phar-
macotherapy does not provide adequate effects in everyday clinical practice [3–5]. The most 
common causes of therapeutic failure are undiscovered secondary causes of hypertension 
and lack of patient/doctor compliance. In about 10% of cases, it can be attributed to resistant 
hypertension caused by a hyperactivity of the sympathetic nervous system [6]. Overactivity 
of the sympathetic nervous system is a condition that confers a high cardio(reno)vascular 
risk to the patient [7, 8]. Renal sympathetic denervation produces multilevel inhibition of 
the sympathetic nervous system and triggers additional positive metabolic effects [9–11]. 
According to the results of different trials with renal sympathetic denervation for control 
of resistant hypertension, including Symplicity HTN-3, renal sympathetic denervation 
seems to be safe, and procedure-related complications of catheter-based renal sympathetic 
denervation were rare. Symplicity HTN-3 study did not show differences in systolic blood 
pressure reduction between treatment and control groups, but in the context of the study 
characteristics and the way it was conducted, there are several concerns about inexperienced 
doctors in the field of renal sympathetic denervation, the study population, and the medical 
treatment [11, 12]. Baroreceptor activation therapy or baropacing can be applied in patients 
with treatment-resistant hypertension too. When baroreceptors sense an increase in carotid 
transmural pressure, they respond by inhibiting sympathetic and stimulating parasympa-
thetic centers in the brainstem [13]. Additional devices could be an option for patients with 
side effect of available antihypertension medications too control blood pressure.
2. Prevalence and etiology of resistant hypertension
The prevalence of resistant hypertension is unknown: epidemiological researches on resistant 
hypertension are missing. The data of frequency can be taken out from observational and 
big controlled clinical studies and is between 10 and 30% among patients with hypertension. 
Etiology of failure to diminish systolic and diastolic blood pressure with a therapeutic plan 
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that includes lifestyle modification and prescription of at least three different drugs in optimal 
doses is heterogeneous. First it is very important to understand the difference between uncon-
trolled (pseudoresistant or apparent) and real resistant hypertension. Potential very common 
reasons for uncontrolled but not resistant hypertension are weight gain (obesity, body mass 
index >30 kg/m2), poor adherence, and the use of drugs such as nonnarcotic analgesics and 
nonsteroidal anti-inflammatory agents by mechanism of causing sodium retention. Other 
lifestyle factors that are associated with resistant hypertension are excessive dietary sodium 
intake and heavy alcohol intake. Secondary causes include unrecognized/untreated obstruc-
tive sleep apnea, primary aldosteronism, chronic parenchymal kidney disease, renal artery 
stenosis, and diabetes. Uncommon causes are pheochromocytoma, Cushing’s disease, aortic 
coarctation, and intracranial tumors. The most common causes of pseudoresistance are poor 
adherence to antihypertensive therapy, white-coat effect, inaccurate measurement of blood 
pressure, pseudo-hypertension, and elderly patients [14, 15]. Other factors contributing to 
nonadherence with antihypertensive medication are African American race, gender (women 
tend to exhibit more nonadherence than men), higher adverse event incidence, polyphar-
macy, and higher drug costs. Poor adherence to antihypertensive therapy is the most impor-
tant cause of unsuccessful blood pressure control. Analyses show that approximately 40% of 
patients will not continue their antihypertensive medications during the first year after diag-
nosing resistant hypertension. During 5–10 years of follow-up, those numbers reach 60% [16].
Inaccurate blood pressure measurement is not uncommon; it occurs when patients are not 
instructed to sit calmly and quietly and when the cuff is too small [17]. In diagnostic algorithm 
of resistant hypertension, stepwise approach is recommended. First is the optimization of 
control of blood pressure by excluding other causes of pseudoresistance. Very common cause 
of pseudoresistance is hypervolemia due to excessive sodium intake/retention, impaired 
kidney function, heart failure, and ineffective use of diuretics. Activity of neuronal sympa-
thetic system which can be produced by chronic stress/pain, hypertension provoked by fear, 
hyperventilation, and vasoconstriction is an additional cause of pseudoresistance. The use 
of drugs like nonsteroidal anti-inflammatory agents, glucocorticosteroids, licorice, erythro-
poietin-stimulating agents, cyclosporine or tacrolimus, antidepressants, sympathicomimet-
ics, oral contraceptives with estrogen, anti-VEGF, cocaine, and amphetamines are very often 
unrecognized cause of pseudoresistance. Undiagnosed secondary hypertension due to kid-
ney diseases, renal artery stenosis, obstructive sleep apnea, or endocrinological disorders is 
the secondary common cause of pseudoresistant hypertension. Inappropriate blood pressure 
measurement and white-coat hypertension have to be excluded before diagnosis of true resis-
tant hypertension. Suspicion of resistant hypertension requires an analysis of drugs which in 
the hypertensive patient is treated with.
3. Risk factors for resistant hypertension
Hypertension is one of the leading modifiable factors in cardiovascular continuum. A hyper-
activity of the sympathetic nervous system is a condition that confers a high cardiovascular 
risk to the patient. Resistant hypertensive patients often have comorbid cardiorenovascular 
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conditions, such as heart failure, atrial fibrillation, and chronic kidney disease. Studies have 
documented independent contribution of sympathetic activation to the cardiorenovascular 
disease [18, 19].
Cardiovascular risk doubles with increase of 20 mmHg systolic blood pressure and 10 mmHg 
diastolic blood pressure [20]. Particularly high cardiovascular risk is in patients with high sys-
tolic blood pressure and normal or low levels of diastolic blood pressure. Patients with chronic 
kidney disease and diabetic patients are special population with high cardiorenovascular 
risk. We do not know the real prevalence of chronic kidney disease in patients with resistant 
hypertension, and the prevalence of resistant hypertension in chronic kidney disease (I–IV 
stages) patients is also underestimated [6]. Obesity as well as chronic kidney disease could 
be the reason of resistance. Other risk factors that are usually related with resistant hyper-
tension have a synergistic effect in development and worsening of resistant hypertension. 
Target-organ damage such as retinopathy, vascular dementia, chronic kidney disease, and 
left ventricle hypertrophy supports a diagnosis of poorly controlled resistant hypertension.
3.1. Cardiovascular risk in resistant hypertension
Higher cardiovascular risk is noted in patients with resistant hypertension and diabetes or 
chronic kidney disease compared to general hypertensive population [19]. If we compared 
with the nonresistant hypertension patients, the resistant hypertension patients had a greater 
prevalence of comorbid conditions like diabetes mellitus (48% vs. 30%), chronic kidney disease 
(45% vs. 24%), ischemic heart disease (41% vs. 22%), and cerebrovascular disease (16% vs. 9%; 
P < 0.001 for all) [19]. Sim and coauthors showed that patients with uncontrolled resistant hyper-
tension (61.7%) are more frequent than controlled. When compared with controlled resistant 
hypertension patients, uncontrolled were at a greater risk for cerebrovascular and end-stage 
renal disease. The risk of end-stage renal disease and cerebrovascular disease was 25% and 23% 
greater, respectively, supporting the linkage between blood pressure and both outcomes [19].
4. Diagnostic workup of resistant hypertensive patients
To determine true resistant hypertension, there is a need to exclude secondary causes of 
resistant hypertension like obstructive sleep apnea, atherosclerosis, and renal or hormonal 
disorders [2]. Diagnostic workup includes clinical examination, laboratory testing, and diag-
nostic methods to identify target organ damage as it is proposed by the European Society of 
Hypertension/European Society of Cardiology [8]. Pseudoresistant hypertension should not 
be confused for the real one in order to avoid unnecessary diagnostic procedures and treat-
ments. Treatment of resistant hypertension involve the correct pharmacological approach, 
reduce therapeutic inertia (the physician), and involve taking medications regularly that have 
been proven to be effective and well tolerated (the patient). Patients have to be engaged in 
their management. There is the need for regular adherence with the prescribed regimen. We 
need diagnosis-based approach that takes into consideration not only a person’s blood pres-
sure but also the overall cardiovascular risk [19, 20].
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4.1. Medical history and clinical examination
The medical history should document duration, severity, and progression of the hyperten-
sion, treatment adherence, and response to prior medications, including adverse events. Very 
important in medical history is current medication use, including herbal and over-the-counter 
medications. Loud snoring, daytime sleepiness, and witnessed apnea indicate obstructive sleep 
apnea. A history of peripheral or coronary atherosclerotic disease and worsening kidney func-
tion are suspicious for renal artery stenosis. Labile hypertension followed by palpitations and 
diaphoresis indicates the possibility of pheochromocytoma. In physical examination, carotid, 
abdominal, or femoral bruits indicate artery stenosis. Moon facies, abdominal striae, and cen-
tral obesity suggest Cushing’s disease. Diminished femoral pulses and difference between arm 
and thigh blood pressures are suspicious for aortic coarctation and/or aortoiliac disease.
4.2. Biochemical evaluation
Biochemical evaluation should include routine metabolic profile such as sodium, potassium, 
chloride, bicarbonate, glucose, blood urea nitrogen, creatinine, albumin/creatinine ratio, 
and estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology 
Collaboration equation and urate level. Reporting of estimated glomerular filtration (eGFR) 
rate is of most importance in recognition of early stages of chronic kidney disease character-
ized with slightly or moderately reduced eGFR and serum creatinine values usually within 
the population-based reference intervals [6]. Even in the setting of ongoing antihypertensive 
treatment, the ratio of aldosterone and renin is a useful diagnostic tool for primary aldo-
steronism, although such high ratio has low specificity and high negative predictive value. 
Additional analysis includes cortisol in 24-h urine and plasma cortisol. A 24-h urine collected 
during ingestion of the patient’s normal diet can be helpful in estimating dietary sodium and 
potassium intake. Measurement of 24-h urinary metanephrines or plasma metanephrines is 
an effective screen for patients in whom pheochromocytoma is suspected.
4.3. Diagnostic methods
Numerous biological and lifestyle factors can contribute to the development of resistant hyper-
tension. Some of them are the following: drugs, obesity or volume overload, diabetes, older 
age, renal diseases, aldosteronism, and obstructive sleep apnea. Less frequent are pheochromo-
cytoma, Cushing’s syndrome, thyroid diseases, and aortic coarctation. In diagnostic approach 
to resistant hypertension, history of a patient is very important, as well as his former adherence, 
adequate measurements of blood pressure, physical state, biochemical tests, and noninvasive 
imaging. It is of high importance that the evaluation of a patient includes 24-h ambulatory 
monitoring of blood pressure (AMBP). “Non-dipper” rhythm in AMBP can be often found in 
high-risk patients, such as chronic kidney patients and patients with obstructive sleep apnea.
The French Society of Hypertension gave the following recommendations for diagnostic 
approach to resistant hypertension: (A) standardized device and an appropriate cuff size 
should be used to avoid poor blood pressure measurement; (B) white-coat effect should be 
eliminated by ambulatory or home blood pressure measurement. Thresholds for uncontrolled 
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hypertension are home blood pressure measurement ≥135/85 mmHg, 24-h ambulatory blood 
pressure measurement ≥130/80 mmHg, daytime ambulatory blood pressure measurement 
≥135/85 mmHg, and nighttime ambulatory blood pressure measurement ≥120/70 mmHg; 
(C) it is necessary to determine if the optimal triple-drug therapy is prescribed; (D) poor patient 
compliance should be assessed using a questionnaire, during drug analysis and pill count; 
and (E) it is suggested to search for factors that could influence treatment resistance (e.g., 
obesity, excessive dietary sodium intake, alcohol, drug interactions) [21]. If the diagnosis of 
resistant hypertension is confirmed, the patient should be referred to a hypertension special-
ist. After true resistant hypertension is confirmed, evaluation should include identification of 
the underlying cause and assessment of cardiovascular risk and end organ damage. Doppler 
of renal arteries, magnetic resonance angiography, or computed tomography angiography 
are highly recommended to assess the anatomy before renal sympatric denervation [21, 19].
5. Treatment strategy of resistant hypertension
Treatment strategy selects the best therapeutic options including lifestyle modifications and 
pharmacological and interventional treatment.
5.1. Lifestyle modifications
Definition of poor or unhealthy lifestyle is sedentary, overweight smoking, or drinking sub-
jects with no exercise habits, on high-salt diet, with negative feelings about medicine [6]. 
More than 60% of patients with resistant hypertension are overweight and obese (12% BMI 
>40 kg/m2) [6]. In both men and women, elevated blood glucose levels, hypertension, obesity, 
and hypercholesterolemia are among the leading risk factors contributing to death and ill-
ness. In an assessment of environmental, occupational, and metabolic risks contributing to 
death and disability, the study reports that tobacco was responsible for more than 7 million 
deaths and poor diet could be blamed for approximately one of five deaths. Appropriate 
lifestyle and dietary measures, smoking cessation, and weight reduction are highly recom-
mended in patients with hypertension [22]. However, little is known about passive smoking 
and secondhand smoke and about the relationship between passive smoking and cardiovas-
cular risk factors. Wu and authors found the positive association between passive smoking 
and blood pressure or hypertension [22]. Higher levels of physical activity have been linked 
to a lower risk of cardiovascular disease and diet. Authors from the Prospective Urban Rural 
Epidemiology (PURE) study, which is one of the world’s largest epidemiological studies, find 
that the form of physical activity has no difference [23]. All of physical activity types are of 
benefit in reducing the risk of cardiovascular disease and premature death. The benefits of 
increased physical activity were seen regardless of whether that activity was recreational, 
occupational, or domestic [23].
5.2. Adherence
Adherence to antihypertensive medication is a key modifiable factor in the management strat-
egy of hypertension. The nature of adherence is multidimensional. Blood pressure control has 
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to be multicomponent and patient-centered interventions to improve adherence. Strategies 
to improve antihypertensive medication adherence and blood pressure control include a 
multilevel approach that combines strategies at the level of the patient and healthcare pro-
vider, organization, and system. Very important are communication skills with hypertension 
patient, information exchange, and simplification of therapy. It is recommended to prefer 
antihypertensive agents with 24-h blood pressure control in once daily dose and fixed dose 
combination. Very important is low cost of antihypertensive agents, especially in low-income 
patients. Tele-health strategies; the use of experienced health professionals for intervention 
devices, especially in the field of renal sympathetic denervation; and self-monitoring of blood 
pressure at home are important too [14]. Treatment compliance must be closely monitored, 
but it is very difficult. The major problem is the lack of persistence of the prescribed regimens. 
Patients should be specifically asked how successful they are in taking all of their prescribed 
doses, including discussion of adverse effects and dosing inconvenience. Family members 
will often provide more objective assessments of a patient’s adherence, but such input should 
generally be in the presence of the patient. Direct observation of therapy is the most accu-
rate method but is impractical for chronic diseases. Methods such as self-reporting or pillbox 
counting are convenient; however, it is easy to manipulate them. The medication event moni-
toring system (MEMS) is a practical improvement, since it records the exact time and date of 
opening the pillbox and it electronically stores this information in the computer (later access 
and control is possible). Such devices seem to be the most reliable for monitoring patients to 
improve their adherence. Blood or urine measurements of drug levels or biologic markers 
are expensive and may falsely suggest adherence in patients who take their medications only 
around the time of their clinic visit or white-coat adherence. In routine clinical practice, it is 
too expensive and not available outside reference centers [14].
5.3. Multidrug therapy
Therapy is not easily applicable to daily clinical practice. Resistant hypertension is defined 
as uncontrolled blood pressure on office measurements, confirmed by out-of-office measure-
ments and the concurrent use of three antihypertensive agents including a thiazide diuretic, 
a renin-angiotensin system blocker (converting enzyme inhibitors (ACE) or angiotensin II 
receptor blockers (ARB)), and long-acting calcium channel blocker, for at least 4 weeks, at 
optimal doses [21]. It is important to choose combination of antihypertensive medication in 
fixed doses to control blood pressure. Some antihypertensive medications have advantage to 
show improvement of arterial elasticity by measuring central blood pressure and pulse wave 
velocity, with alleviation of insulin resistance and inflammation. Multidrug therapy includes 
adding a mineralocorticoid receptor antagonist (aldosterone antagonists) such as spironolac-
tone and eplerenone. Dosage of spironolactone or eplerenone is 12.5–25 mg/day. Both drugs 
are effective for resistant hypertension but have sexual side effects and can lead to hyperka-
lemia especially in patients with diabetes and chronic kidney disease [24]. If adverse effects 
occur, or in a case of a nonresponse, a β-blocker, an α-blocker, or a centrally acting antihy-
pertensive drug should be prescribed. General clinical examination and 24-h blood pressure 
monitoring have to be performed in all patients at baseline and after minimum 4 weeks of 
therapy to confirm resistant hypertension. In the case of failure to control blood pressure with 
antihypertensive multimodal regiment, with a nasal continuous positive airway pressure 
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ventilation in patients with obstructive sleep apnea of moderate to severe degree and resistant 
hypertension, renal sympathetic denervation or baroreceptor activation therapy may create a 
novel pathway of blood pressure control in true or proven resistant hypertension.
5.4. Device therapies for resistant hypertension
The sympathetic nervous system is very important and a forgotten pathway in hyperten-
sion treatment. It is very uncommon than in national and international society, guidelines for 
hypertension typically put antiadrenergic drugs to the fourth of fifth place. Many of the pro-
cedures/devices target the sympathetic nervous system and effectively and safely lower blood 
pressure in patients with resistant hypertension [24]. New device therapy can give additional 
control of true resistant hypertension. Renal sympathetic denervation, baroreceptor activa-
tion therapy, and continuous positive airway pressure were developed to interrupting the 
cardiovascular disease continuum, the leading cause of death globally.
5.4.1. Catheter-based renal denervation
Renal sympathetic denervation delivers energy to the renal nerves to help control blood pres-
sure. Renal sympathetic denervation uses ablation of the renal sympathetic nerves with a 
radiofrequency-emitting catheter inserted percutaneously through the femur into the lumen 
of both renal arteries. Renal sympathetic denervation causes moderately severe abdominal 
pain during delivery of energy due to stimulation of the renal sensory nerves before abla-
tion. During the procedures the use of opiates and sedatives is important to control pain. The 
procedure reduces sympathetic outflow from the brain which is evident in lowering of nor-
adrenalin on plasma and in reduction of sympathetic nerve traffic to the skeletal muscle vas-
culature [24]. Many observational studies have shown that renal sympathetic denervation is 
a safe method of reducing office blood pressure in patients with resistant hypertension. Renal 
sympathetic denervation showed an additional positive effect on blood glucose metabolism, 
obstructive sleep apnea, and signs of hypertensive end organ damage [9]. The reason for the 
rapid introduction of renal sympathetic denervation in the therapy of resistant hypertension 
was the reported high efficiency and safety of the procedure [2, 10]. The effectiveness was 
demonstrated in the studies Symplicity HTN-1 and HTN-2 and in the EnligHTN-1 Study, 
by using special radiofrequency ablation catheters [10, 11]. Renal sympathetic denervation, 
according to the results of different trials, including Symplicity HTN-3, seems to be safe, and 
procedure-related complications of catheter-based renal sympathetic denervation were rare 
[11, 12]. Symplicity HTN-3 study did not show differences in systolic blood pressure reduc-
tion between treatment and control groups, but in the context of the study characteristics and 
the way it was conducted, there were several concerns about inexperienced doctors in the field 
of renal sympathetic denervation, the study population, and the medical treatment. Patients 
with diabetes and/or chronic kidney disease have sympathetic nervous system hyperactiva-
tion that leads to fluid overload, aggravation of hypertension, and further deterioration and 
loss of renal function. It has been demonstrated that renal sympathetic denervation is asso-
ciated with stabile kidney function in those patients [11, 12]. Future focus is on long-term 
results of renal sympathetic denervation.
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5.4.2. Baroreceptor activation therapy
Baropacing or baroreceptor activation therapy can be applied in patients with treatment-
resistant hypertension. When baroreceptors sense an increase in carotid transmural pres-
sure, they respond by inhibiting sympathetic and stimulating parasympathetic centers in the 
brainstem [13]. So any increase in blood pressure will return to its initial level. Most studies 
on baropacing took only office blood pressure as criterion for efficacy, but only one study in 
which the effect on 24-h was assessed showed that blood pressure had fallen by 8/5 mmHg 
after 6 months [13].
5.4.3. Continuous positive airway pressure
Nasal continuous positive airway pressure ventilation is considered the treatment for obstruc-
tive sleep apnea of moderate to severe degree [25]. The effects of continuous positive airway 
pressure on blood pressure levels have been shown to be variable, but in some subgroups of 
patients, those with severe obstructive sleep apnea or/and with resistant hypertension, more 
substantial effects of continuous positive airway pressure have been reported [24].
6. Discussion
Hypertension is the most prevalent risk factor for cardiovascular disease and death all around 
the world [19]. Physical activity has to be as part of our lives that is beneficial and it is a 
low-cost preventive strategy [24]. Lifestyle changes include weight loss, ingestion of a high-
fiber, low-fat, low-salt diet, and moderation of alcohol intake. Good blood pressure control 
lowers risk for cardiovascular events. Despite the available pharmacological antihyperten-
sive therapy, about 50% of patients show suboptimal control. Resistant hypertension patients 
often have comorbid cardiorenovascular conditions, such as heart failure, atrial fibrillation, 
or chronic kidney disease [20]. Hypertensive disease of the heart, blood vessels, brain (espe-
cially vascular dementia), and kidney is frequently found in patients with RH. The diagnosis 
of hypertension and treatment are based usually on daytime clinic blood pressure measure-
ments. Evidence is that the asleep blood pressure better predicts cardiovascular events than 
the awake or 24-h blood pressure mean. The comparative outcomes in resistant hypertension 
deserve better understanding, and results from the Global SYMPLICITY registry (real life) 
showed that renal sympathetic denervation may provide an additional treatment option to 
reduce blood pressure in resistant hypertension patients with obstructive sleep apnea [26]. 
New data show that renal sympathetic denervation, by modulating the sympathetic system 
activation, could have an additional beneficial effect on blood pressure variability. The level 
of blood pressure is very important, but pattern of fluctuation of blood pressure within 24 h 
or variability from day to years is related to cardiorenovascular morbidity and mortality, 
independently of comorbidities [27].
It is important to keep the regimens for the resistant hypertension management as simple as 
possible. It means not only for blood pressure management but all concomitant comorbidities. 
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Screening and management of multisite artery disease is very important in diagnostic algo-
rithm of resistant hypertension. In terms of costs, there is no question pharmacoeconomically 
that effective blood pressure control in resistant hypertension with drugs and new innova-
tive device therapies is cheaper than treating the consequences of hypertensive target organ 
damage [28]. To assess drug adherence of patients with resistant hypertension in the future, 
an analytical method is developed in the Netherlands. Ultra-performance liquid chromatog-
raphy tandem mass spectrometry (UPLC-MS/MS) is being used for validation of eight fre-
quently prescribed antihypertensive drugs from four classes and their active metabolites in 
plasma. It includes enalapril and perindopril as angiotensin-converting enzyme inhibitors 
and enalaprilat and perindoprilat (their active metabolites), as well as angiotensin II recep-
tor blockers losartan. Furthermore, UPLC-MS/MS includes active metabolite losartan carbox-
ylic acid and valsartan, nifedipine, and calcium channel blockers amlodipine and diuretics 
(hydrochlorothiazide and spironolactone with the active metabolite canrenone) [29]. Resistant 
hypertension should not be considered as a synonym for uncontrolled hypertension. The 
latter covers all patients with hypertension: (a) whose lacking blood pressure control is not 
undergoing therapy, (b) who had an inadequate therapy, (c) those hypertensive patients with 
poor compliance, (d) those with secondary hypertension, and (e) those who are truly resistant 
to therapeutic treatment. Even though the definition of resistant hypertension is inconsistent 
regarding the number of necessary antihypertensive drugs, it is as a concept directed toward 
identifying the patients with high risk of target organ damage, reversible causes for hyperten-
sion and/or patients who will use special diagnostic and therapeutic options due to perma-
nently high level blood pressure [30]. Therapeutic restoration of normal physiologic blood 
pressure reduction during nighttime sleep (circadian variation) is the most significant inde-
pendent predictor of decreased cardiorenovascular risk and the basis for the chronotherapy 
[30]. Although chronotherapy is not uniformly recommended in the treatment of resistant 
hypertension, it is a cost-effective strategy for reducing cardiovascular risk.
7. Conclusions
Due to higher cardiovascular risk, resistant hypertension is serious and requires special diag-
nosis and treatment of multidisciplinary team of hypertension specialist, nephrologist, inter-
ventional cardiologist or radiologist, and nurse.
It is important that patients understand the rationale for good adherence to antihypertensive 
therapy. Poor adherence is a major cause of lack of blood pressure control, and it can be mis-
leading in further diagnostics and treatment with detection of drugs in blood and/or urine. 
New devices were developed to interrupting the cardiovascular disease continuum, the lead-
ing cause of death globally. New devices for hypertension should only be prescribed by a 
specialist hypertension clinic. Recently published interim result from the SPYRAL HTN-OFF 
MED study showed that more intensive approach to ablating renal nerves that the one used 
in the failed SYMPLICITY HTN-3 trial can reduce blood pressure in a patient with untreated 
mild to moderate hypertension. It provides biological proof of principle for the efficacy of 
renal sympathetic denervation [31].
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